Welcome to our dedicated page for Adial Pharmaceuticals SEC filings (Ticker: ADIL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Adial is a clinical-stage biopharmaceutical company focused on therapies for addictions and related disorders, and its filings document both the scientific and financial aspects of this development-stage business.
Investors can review Current Reports on Form 8-K that describe material events such as End of Phase 2 (EOP2) meeting outcomes with the U.S. Food and Drug Administration (FDA), Nasdaq listing compliance notices, equity offerings, at-the-market sales agreements, warrant amendments, and stockholder approvals for changes to the Certificate of Incorporation and equity incentive plans. These filings provide detail on the regulatory feedback shaping the AD04 Phase 3 adaptive trial design, including biomarker-positive and biomarker-negative cohorts, primary efficacy endpoints based on heavy drinking days, and statistical planning.
Filings also outline capital structure and financing arrangements, including best efforts public offerings of common stock and warrants, pre-funded warrants, and at-the-market programs. Disclosures explain how proceeds are intended for working capital and general corporate purposes and describe conditions such as exercise prices, expiration dates, and stockholder approval requirements for warrant exercises.
Through Stock Titan, users can track Nasdaq listing and compliance disclosures, including letters regarding stockholders’ equity thresholds, minimum bid price requirements, and extensions granted to regain compliance. These documents help clarify the ongoing eligibility of ADIL shares for trading on the Nasdaq Capital Market.
In addition to raw documents, Stock Titan offers AI-powered summaries that highlight key points from Adial’s 8-Ks and other filings, helping readers quickly understand complex topics such as clinical trial design guidance, intellectual property steps around AD04, and changes to authorized share counts or incentive plans. This page is a resource for anyone analyzing how Adial’s regulatory, clinical, and financing activities are reflected in its official SEC record.
Adial Pharmaceuticals reported FDA feedback supporting its adaptive trial design for AD04 in alcohol use disorder (AUD). The FDA recognized AUD as an unmet need and agreed with core protocol elements including biomarker-defined positive and negative cohorts, inclusion criteria targeting moderate-to-severe AUD, trial duration, interim analysis sample size, and safety monitoring. The agency confirmed the primary efficacy endpoint of zero heavy drinking days during months 5 and 6 of the efficacy observation period and advised pre-specifying key secondary endpoints for labeling consideration. FDA also reviewed the planned interim analyses, the Statistical Analysis Plan, and the Data Monitoring Committee structure, stressing alignment among protocol, simulation report, and SAP to ensure proper alpha control and reduce post-trial analysis risk.
Adial Pharmaceuticals, Inc. filed a Form S-8 registering shares for its employee benefit plans and incorporates prior registration statements and corporate documents by reference. The filing references prior S-8 registrations that, after the 1-for-25 reverse stock split, correspond to registered blocks of 70,000, 80,000 and other shares, and notes an additional 1,500,000 shares registered on December 12, 2024. The filing lists governing documents, equity plan amendments, legal opinions, auditor consents and officers and directors who signed the registration statement.
Adial Pharmaceuticals received a Nasdaq notice granting an additional 180 days, until March 2, 2026, to regain compliance with the $1.00 minimum bid price required for continued listing on the Nasdaq Capital Market.
The company must have its stock close at or above $1.00 per share for at least ten consecutive business days, and it has told Nasdaq it may use a reverse stock split, if needed, to cure the deficiency, completing any split at least ten business days before the deadline. If Adial fails to regain compliance by March 2, 2026, Nasdaq staff may move to delist the shares, though the company would have the right to appeal to a hearings panel.
Adial Pharmaceuticals, Inc. furnished an update on its financial results by issuing a press release that includes financial information for the fiscal quarter ended June 30, 2025. The company submitted this press release as Exhibit 99.1 to a current report on Form 8-K.
The company states that the press release and related Item 2.02 information are being furnished rather than filed, meaning they are not subject to certain liability provisions of the federal securities laws and will not automatically be incorporated by reference into other SEC filings.
Adial Pharmaceuticals (ADIL) is a clinical-stage biopharmaceutical company developing AD04 for alcohol use disorder with a precision‑medicine genetic focus. At June 30, 2025 the company held $5.9 million in cash and cash equivalents and reported a $4.19 million net loss for the six months ended June 30, 2025, leaving an accumulated deficit of $86.2 million.
Management received approximately $5.3 million of net proceeds from warrant exercises and equity issuances in May–June 2025 and completed a June 2025 best efforts offering that generated about $3.0 million net. The company states these funds are sufficient to meet current commitments into the second quarter of 2026 but explicitly notes substantial doubt about its ability to continue as a going concern and that additional capital will be required for planned Phase 3 trials.
Key operational positives disclosed include a favorable FDA response on an in‑vitro bridging strategy and an issued U.S. patent (April 15, 2025) covering AD04 administration for patients with specified genetic markers. The filing also discloses material weaknesses in internal controls and multiple warrant programs and shareholder approvals that create meaningful potential dilution.